Fair Accountability and Innovative Research Drug Pricing Act of 2017
Latest action · May 19, 2017 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMay 16, 2017
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Fair Accountability and Innovative Research Drug Pricing Act of 2017
This bill amends the Public Health Service Act to require manufacturers of certain drugs and biological products with a wholesale cost of $100 or more per month to report to the Department of Health and Human Services (HHS) price increases that result in a 10% or more increase in the cost of a drug over a 12-month period or a 25% or more increase over a 36-month period. Reports are required for prescription drugs and drugs commonly administered in hospitals, except vaccines, drugs for rare conditions, and drugs with annual sales for Medicare and Medicaid enrollees of less than $1. Reports must contain specified information including pricing history and a justification for each price increase in the relevant period.
Manufacturers that do not submit a required report are subject to a civil penalty. Collected penalty funds must be used to carry out activities related to this reporting requirement and to improve consumer and provider information about drug value and drug price transparency.
HHS must publish manufacturer reports, a summary of those reports, and supporting analyses.Cosponsors 24
Members who signed on, in the order they did. Signatures ran from May 16, 2017 to Oct 2, 2018; 4 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-MD | Elijah E. Cummings | Original | May 16, 2017 |
| D-TX | Lloyd Doggett | Original | May 16, 2017 |
| D-VT | Peter Welch | Original | May 16, 2017 |
| D-CT | Rosa L. DeLauro | Original | May 16, 2017 |
| D-KY | John A. Yarmuth | Jul 12, 2017 | |
| D-FL | Kathy Castor | Sep 6, 2017 | |
| D-TN | Steve Cohen | Sep 6, 2017 | |
| D-ME | Chellie Pingree | Sep 14, 2017 | |
| D-NM | Michelle Lujan Grisham | Feb 13, 2018 | |
| D-WI | Mark Pocan | Mar 5, 2018 | |
| D-PA | Michael F. Doyle | Mar 5, 2018 | |
| D-MN | Timothy J. Walz | Mar 5, 2018 | |
| D-MS | Bennie G. Thompson | Mar 19, 2018 | |
| D-DC | Eleanor Holmes Norton | Mar 19, 2018 | |
| D-MO | Emanuel Cleaver | Apr 11, 2018 | |
| D-CA | Judy Chu | Apr 24, 2018 | |
| D-MD | Jamie Raskin | Jun 5, 2018 | |
| D-AZ | Raúl M. Grijalva | Jun 5, 2018 | |
| D-TX | Sheila Jackson Lee | Jun 5, 2018 | |
| D-CA | Ro Khanna | Jul 25, 2018 | |
| R-FL | Francis Rooney | Jul 26, 2018 | |
| D-MN | Betty McCollum | Aug 3, 2018 | |
| R-NY | Peter T. King | Sep 26, 2018 | |
| D-CA | Ted Lieu | Oct 2, 2018 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred May 16, 2017 |
| Health Subcommittee | Referred May 19, 2017 |
Actions 3
Everything that happened, newest first.
- May 19, 2017Referred to the Subcommittee on Health.
- May 16, 2017Introduced in House
- May 16, 2017Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 163, no. 84, May 16, 2017, page H4223.
Printed hearings 1
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| Serial No. 115-147 | OPPORTUNITIES TO IMPROVE THE 340B DRUG PRICING PROGRAM178 pages | Energy and Commerce Committee | Jul 11, 2018 |
Related bills 2
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 1131 | Fair Accountability and Innovative Research Drug Pricing Act of 2017 | Related bill | May 16, 2017 |
| HR 2296 | More Efficient Tools to Realize Information for Consumers Act | Reintroduced Bill | Sep 24, 2019 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To require reporting regarding certain drug price increases, and for other purposes.
- Short Titles as Introduced
- Fair Accountability and Innovative Research Drug Pricing Act of 2017
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- May 16, 2017Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.